What clinical studies have been performed on Enteromix (a probiotic containing Lactobacillus and Bifidobacterium)?

Enteromix Clinical Studies

I cannot identify any specific clinical studies on a product called "Enteromix" in the available evidence. However, if Enteromix contains Lactobacillus and Bifidobacterium species, the following evidence applies to similar probiotic combinations:

Evidence for Multi-Strain Lactobacillus/Bifidobacterium Combinations

The most extensively studied multi-strain probiotic containing Lactobacillus and Bifidobacterium species is an 8-strain combination, which has been tested in multiple conditions with varying results. 1

Pouchitis (Strongest Evidence)

• The 8-strain combination (L. paracasei, L. plantarum, L. acidophilus, L. delbrueckii subsp bulgaricus, B. longum subsp longum, B. breve, B. longum subsp infantis, and S. thermophilus) demonstrated significant benefit for maintenance of remission in chronic pouchitis (RR 20.24; 95% CI 4.28-95.81) 1
• Two studies showed potential benefit for preventing initial episodes of acute pouchitis (RR 1.29; 95% CI 1.03-1.61), though evidence quality was very low 1
• The AGA conditionally recommends this specific 8-strain combination for pouchitis patients 1

Irritable Bowel Syndrome (Limited Evidence)

• Two RCTs tested the 8-strain combination in 73 adults with IBS, showing decreased abdominal pain scores (mean decrease 3.78; 95% CI 4.93-2.62), but sample size was small with unclear risk of bias 1
• The AGA recommends probiotics for IBS only in clinical trial contexts due to very low quality evidence across 76 RCTs testing 44 different probiotic combinations 2, 3
• Most individual probiotic studies showed benefit in only single small trials that were never replicated 1, 2

Ulcerative Colitis (Insufficient Evidence)

• Four studies compared the 8-strain combination to mesalamine for induction of remission, suggesting potential benefit but with very low certainty (RR 1.72; 95% CI 0.78-3.32) 1
• The AGA recommends probiotics for ulcerative colitis only within clinical trials due to heterogeneity and low-quality evidence 1

Pediatric Functional Abdominal Pain (Mixed Evidence)

• Probiotics containing Lactobacillus and Bifidobacterium species may achieve treatment success compared to placebo (RR 1.57; 95% CI 1.05-2.36), but evidence is low certainty 4
• Complete pain resolution showed no clear difference (RR 1.55; 95% CI 0.94-2.56) with very low certainty evidence 4

Critical Limitations Across All Studies

Publication bias is a major concern—numerous registered protocols yielded no peer-reviewed publications or publicly available results 1, 3

• The overall certainty of evidence across gastrointestinal conditions ranges from low to very low 1, 2
• Most studies had small sample sizes, heterogeneous patient populations, and variable study designs 1
• Results cannot be generalized between different probiotic strains or combinations 5
• No serious adverse events were reported in included studies, though withdrawal rates due to adverse events showed no difference from placebo 4

Clinical Bottom Line

Without knowing the exact strain composition and dosing of "Enteromix," no specific recommendations can be made. If it contains the specific 8-strain combination listed above, consider it only for pouchitis patients where conditional evidence exists 1. For IBS, functional abdominal pain, or inflammatory bowel disease, recommend evidence-based first-line therapies instead: soluble fiber (psyllium 3-4 g/day), regular exercise, low FODMAP diet, or brain-gut behavioral therapies 2, 3.